~8 spots leftby Dec 2025

Exercise for Sarcopenia

Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: University of Texas at Austin
No Placebo Group
Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

Participants will be 60-80 y men and women who vary their physical activity (steps/day) while their lipid metabolism is studied (n=24). Thereafter, another group (n=60) will perform 6 months of exercise training focused on developing maximal cycling power, during which their changes in muscle mass and practical function will be carefully measured.

Research Team

Eligibility Criteria

This trial is for relatively healthy men and women aged between 60-80 years who are interested in participating in an exercise program to combat muscle loss (sarcopenia) and improve heart health. Those considered relatively unhealthy cannot participate.

Inclusion Criteria

Relatively healthy

Exclusion Criteria

This criterion is not specific enough to provide a clear understanding. Can you please provide additional details or context for this criterion?

Treatment Details

Interventions

  • Exercise (Behavioural Intervention)
Trial OverviewThe study involves two parts: initially, participants will vary their daily physical activity while researchers study changes in fat metabolism. Then, a second group will undergo six months of exercise training aimed at increasing cycling power to see how it affects muscle mass and function.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ExerciseExperimental Treatment1 Intervention
Six months of power training

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Texas at Austin

Lead Sponsor

Trials
387
Recruited
86,100+
Dr. Elly Barry profile image

Dr. Elly Barry

University of Texas at Austin

Chief Medical Officer

MD from Harvard Medical School

Dr. Brian Windsor profile image

Dr. Brian Windsor

University of Texas at Austin

Chief Executive Officer since 2023

PhD in Molecular Biology from the University of Texas at Austin